Genprex Inc
genprex.comWhat Do They Do?
Develops gene therapies for people with lung cancer and diabetes, including REQORSA and candidates designed to treat diabetes.
10-K for FY2025, filed Mar 30, 2026We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet…View ↗
Our lead oncology drug candidate, REQORSA® Gene Therapy (generic name: quaratusugene ozeplasmid), previously referred to as GPX-001, is…View ↗
In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2024, filed Apr 1, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$4.4MView ↗
- ▼ −5% (Loss)
- vs −$4.7M in Q2 FY2025
-
Aug 5, 2026
Genprex regained Nasdaq minimum bid-price compliance
The Nasdaq panel requires the company to maintain a closing bid price of at least $1.00 each trading day through December 7, 2026.
Sources
8-K, filed Aug 5, 2026
On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price…View ↗
Diabetes candidate scope
The earlier report described distinct candidates for diabetes; the latest report describes a shared candidate across the diabetes program.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of…View ↗
In diabetes, we have exclusively licensed from the University of Pittsburgh of the Commonwealth System of Higher Education (“University of…View ↗
Loading...
